Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure

Cardiovascular Research

Volumn 37, Issue 3, 1998, Pages 667-675

  Feng, Qingping ^a   Xiangru, Lu ^a   Fortin, Amanda J ^a   Pettersson, Anders ^b   Hedner, Thomas ^b   Kline, Robert L ^a   Arnold, J Malcolm O ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Asymmetric dimethylarginine (ADMA); Congestive heart failure; Endothelium; L Arginine; Nitric oxide; Nitric oxide synthase Inhibitor; Rat; Renal function

Indexed keywords

4 AMINOHIPPURIC ACID; ACETYLCHOLINE; ARGININE; DIMETHYLARGININE; INULIN; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

4 AMINOHIPPURIC ACID CLEARANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; FLUORESCENCE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INULIN CLEARANCE; KIDNEY BLOOD FLOW; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THORACIC AORTA; VASODILATATION;

ACETYLCHOLINE; ANIMALS; AORTA, THORACIC; ARGININE; ENDOTHELIUM, VASCULAR; HEART FAILURE, CONGESTIVE; KIDNEY; MALE; METABOLIC CLEARANCE RATE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE; ORGAN CULTURE TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; RENAL CIRCULATION; VASODILATION; VASODILATOR AGENTS;

EID: 0032029297     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00242-3     Document Type: Article

References (41)

1. [1] Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. [Review]. Pharmacol Rev 1991;43:109-142.
2. [2] Feng QP, Hedner T. Endothelium-derived relaxing factor (EDRF) and nitric oxide (NO). I and II. Physiology, pharmacology and pathophysiological implications. [Review]. Clin Physiol 1990;10:407-426.
3. [3] Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988;333:664-666.
4. [4] Rees DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989;86:3375-3378.
5. G-dimethylarginine, N∈-mono, di, and trimethyllysine, and glucosylgalactosyl- and galactosyl-δ-hydroxylysine from human urine. J Biol Chem 1970;245:5751-5758.
6. [6] Park KS, Lee HW, Hong SY, Shin S, Kim S, Paik WK. Determination of methylated amino acids in human serum by high-performance liquid chromatography. J Chromatogr 1988;440:225-230.
7. [7] Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
8. [8] Azuma H, Sato J, Hamasaki H, Sugimoto A, Isotani E, Obayashi S. Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells. Br J Pharmacol 1995;115:1001-1004.
9. [9] Feng QP, Hedner T, Andersson B, Lundberg JM, Waagstein F. Cardiac neuropeptide Y and noradrenaline balance in patients with congestive heart failure. Br Heart J 1994;71:261-267.
10. [10] Feng QP, Bergdahl A, Lu XR, Sun XY, Edvinsson L, Hedner T. Vascular alpha-2 adrenoceptor function is decreased in rats with congestive heart failure. Cardiovasc Res 1996;31:577-584.
11. [11] Feng QP, Carlsson S, Thoren P, Hedner T. Characteristics of renal sympathetic nerve activity in experimental congestive heart failure in the rat. Acta Physiol Scand 1994;150:259-266.
12. [12] Ontkean M, Gay R, Breenberg B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res 1991;69:1088-1096.
13. [13] Drexler H, Hayoz D, Munzel T, Hornig B, Just H, Brunner HR, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992;69:1596-1601.
14. [14] Kiuchi K, Sato N, Shannon RP, Vatner DE, Morgan K, Vatner SF. Decreased β-adrenergic receptor-and endothelium-mediated vasodilation in conscious dogs with heart failure. Circ Res 1993;73:1013-1023.
15. [15] Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991;84:1589-1596.
16. [16] Feng QP, Hedner T, Hedner J, Pettersson A. Blunted renal response to atrial natriuretic peptide in congestive heart failure rats is reversed by the alpha 2-adrenergic agonist clonidine. J Cardiovasc Pharmacol 1990;16:776-782.
17. [17] Feng QP, Carlsson S, Thoren P, Hedner T. Effects of clonidine on renal sympathetic nerve activity, natriuresis and diuresis in chronic congestive heart failure rats. J Pharmacol Exp Ther 1992;261:1129-1135.
18. [18] Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985;72:406-412.
19. [19] Mannesmann G, Muller B. Measurement of cardiac output by the thermodilution method in rats: The effect of different volumes and temperatures of the indicator solution on cardiac output measurements and on cardiodynamics and hemodynamics of the anesthetized rat. J Pharmacol Methods 1980;4:11-18.
20. [20] Kline RL, Liu F. Modification of pressure natriuresis by long-term losartan in spontaneously hypertensive rats. Hypertension 1994;24:467-473.
21. [21] Aneman A, Backman V, Snygg J, von Bothmer C, Fandriks L, Pettersson A. Accumulation of an endogenous inhibitor of nitric oxide synthase during graded hemorrhagic shock. Circ Shock 1994;44:111-114.
22. [22] Smith CJ, Sun D, Hoegler C, Roth BS, Zhang X, Zhao G, et al. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Circ Res 1996;78:58-64.
23. [23] Feng QP, Lu XR, Scott J, McCormack DG, Arnold JMO. Calcium dependent nitric oxide synthase activity is decreased while calcium independent nitric oxide synthase activity is increased in aorta of rats with congestive heart failure. J Am Coll Cardiol 1996;27(suppl A):113A.
24. [24] Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-241.
25. [25] Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM. Tumor necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996;347:1151-1155.
26. [26] Yoshizumi M, Perrella MA, Burnett JCJ, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993;73:205-209.
27. [27] Canty JMJ, Schwartz JS. Nitric oxide mediates flow-dependent epicardial coronary vasodilation to changes in pulse frequency but not mean flow in conscious dogs after pacing induced heart failure. Circulation 1994;89:375-384.
28. [28] Singh N, Dhalla AK, Seneviratne C, Singal PK. Oxidative stress and heart failure. [Review]. Mol Cell Biochem 1995;147:77-81.
29. G-dimethyl-L-arginine and their reversibility by vasodilators in conscious rats. Br J Pharmacol 1993;110:1457-1464.
30. [30] MacAllister RJ, Pickling SA, Whitley GS, Vallance P. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol 1994;112:43-48.
31. [31] Hirooka Y, Imaizumi T, Tagawa T, Shiramoto M, Endo T, Ando S, et al. Effects of L-arginine on impaired acetylcholine-induced and ischemic vasodilation of the forearm in patients with heart failure. Circulation 1994;90:658-668.
32. [32] Mehta S, Stewart DJ, L D, Levy RD. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation 1995;92:1539-1545.
33. [33] Rector TS, Bank AJ, Mullen KA, Tschumperlin LK, Sih R, Pillai K, et al. Randomized, double-blind, placebo-controlled study of supple-mental oral L-arginine in patients with heart failure. Circulation 1996;93:2135-2141.
34. [34] Boger RH, Bode-Boger SM, Gerecke U, Frolich JC. Long term administration of L-arginine, L-NAME, and the exogenous NO donor molsidomine modulates urinary nitrate and cGMP excretion in rats. Cardiovasc Res 1994;28:494-499.
35. [35] Palmer JP, Walter RM, Ensick JW. Arginine-stimulated acute phase of insulin and glucagon secretion. I. In normal man. Diabetes 1975;24:735-740.
36. [36] Rakoff JS, Siler TM, Sinha YN, Yen SSC. Prolactin and growth hormone release in response to sequential stimulation by arginine and TRF. J Clin Endocrinol Metabolism 1973;37:641-644.
37. [37] Pieper GM, Peltier BA. Amelioration by L-arginine of a dysfunctional arginine/nitric oxide pathway in diabetic endothelium. J Cardiovasc Pharmacol 1995;25:397-403.
38. [38] Cantoni GL. Biological methylation: selected aspects. Ann Rev Biochem 1975;44:435-451.
39. G-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 1989;264:10205-10209.
40. [40] Hostetter TH, Pfeffer JM, Pfeffer MA, Dworkin LD, Braunwald E, Brenner BM. Cardiorenal hemodynamics and sodium excretion in rats with myocardial infarction. Am J Physiol 1983;245:H98-H102.
41. [41] DiBona GF, Herman PJ, Sawin LI. Neuronal control of renal function in edema forming states. Am J Physiol 1988;254:R1017-R1024.